Lithiasis, Nephrolithiasis
Conditions
Brief summary
The extracorporeal shock wave lithotripsy (ESWL) is the treatment of choice for most stones in any of their locations. It is about breaking the stone without surgically intervening on the patient and getting him to expel the fragments himself. It is thought that additional treatments to the ESWL could improve the success rate of ESWL for less favorable stones. The components of our authorized food supplement have shown an inhibitory effect in vitro on the growth of calcium oxalate monohydrate crystals, even in hightly supersaturared solutions. Also these components show an inhibitory effect on the growth of calcium phosphate crystals. To sum up, it reduces the formation, inhibits the growth and promotes the dissolution of calcium oxalate and calcium phosphate kidney stones. This is the reason why this experimental study aims to modify the size limit of the stones in the ESWL with adjuvant food supplement.
Detailed description
The study treatment will be administered for 10 weeks. First, one dose will be administered every 12 hours for each patient during the 4 weeks prior to ESWL. After ESWL, and for 6 weeks, one dose will be administered every 24 hours.
Interventions
DIETARY_SUPPLEMENTFood supplement
FagolitosPlus® is an authorized food supplement that contains hydroxycitric acid, vitamin complexes and ions.
DIETARY_SUPPLEMENTPlacebo
Placebo has a composition that makes the weight and organoleptic characteristics are identical to FagolitosPlus®.
Sponsors
Arafarma Group, S.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Renal lithiasis with high radiological and clinical suspicion of calcium oxalate or calcium phosphate, size of the largest diameter between 1.5x1cm and 2x1cm, which will be treated by ESWL, being symptomatic with little probability of spontaneous expulsion. * Signed informed consent to participate in the clinical study.
Exclusion criteria
* Lithiasis of more than 20 mm and less than 15 mm for the largest diameter. * Taking medications with influence on urinary lithogenesis (citrate, bicarbonate, thiazides, bisphosphonates, magnesium, calcium, vitamin B6, vitamin D, vitamin A, xanthine-oxidase inhibitors, uricosurics, probiotics, urease inhibitors, cystine binders, topiramate , antiretrovirals). * Taking medications that influence urine pH (citrate, bicarbonate, carbonic anhydrase inhibitors, L-methionine, vitamin C, ammonium chloride). * Taking selective serotonin reuptake inhibitor antidepressant medications. * Taking anticoagulants and antiaggregants. * ESWL contraindications: urine infection, active or recurrent; hemorrhagic diathesis; pregnant or lactating patients; others (extreme obesity, arterial aneurysm near the location of the stone, etc.).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Efficacy of extracorporeal shock wave lithotripsy (ESWL) measured as reduction of the size (area) of lithiasis between both treatment groups. | 10 weeks after baseline visit | To assess the level of fragmentation of lithiasis which is treated with ESWL by measuring the % of reduction of the size (area) of lithiasis through imaging tests. |
| Efficacy of extracorporeal shock wave lithotripsy (ESWL) measured as number of generated fragments between both treatment groups. | 10 weeks after baseline visit | To assess the level of fragmentation of lithiasis which is treated with ESWL by measuring the number of generated fragments through imaging tests. |
| Efficacy of extracorporeal shock wave lithotripsy (ESWL) measured as the hardness of lithiasis between both treatment groups. | 10 weeks after baseline visit | To assess the level of fragmentation of lithiasis which is treated with ESWL by measuring the hardness of lithiasis through imaging tests. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of morbidities related to the ESWL between both treatment groups. | 2 weeks and 6 weeks after ESWL | All episodes of morbidities related to the ESWL will be recorded, whether considered relevant. |
Countries
Spain
Outcome results
None listed